Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
52
IDYA Quote, Financials, Valuation and Earnings
Last price:
$35.71
Seasonality move
:
-9.78%
Day range:
$35.19 - $35.92
52-week range:
$13.45 - $37.08
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
14.69x
P/B ratio:
2.86x
Volume:
355.1K
Avg. volume:
957.8K
1-year change:
41.03%
Market cap:
$3.1B
Revenue:
$7M
EPS (TTM):
-$1.86
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IDYA
IDEAYA Biosciences, Inc.
|
$60M | -$0.55 | -15.05% | -37.84% | $49.65 |
|
GTBP
GT Biopharma, Inc.
|
-- | -- | -- | -- | $8.00 |
|
PFE
Pfizer Inc.
|
$16.5B | $0.63 | -4.58% | 694.41% | $28.62 |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.6B | $9.64 | -0.81% | 32.75% | $788.28 |
|
RZLT
Rezolute, Inc.
|
-- | -$0.26 | -- | -19.96% | $4.13 |
|
SRPT
Sarepta Therapeutics, Inc.
|
$337M | -$0.37 | -42.37% | -91.57% | $20.61 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IDYA
IDEAYA Biosciences, Inc.
|
$35.68 | $49.65 | $3.1B | -- | $0.00 | 0% | 14.69x |
|
GTBP
GT Biopharma, Inc.
|
$0.85 | $8.00 | $9M | -- | $0.00 | 0% | 59.35x |
|
PFE
Pfizer Inc.
|
$25.03 | $28.62 | $142.3B | 14.59x | $0.43 | 6.87% | 2.28x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$783.71 | $788.28 | $82.4B | 18.76x | $0.88 | 0.45% | 6.06x |
|
RZLT
Rezolute, Inc.
|
$2.74 | $4.13 | $254.1M | -- | $0.00 | 0% | -- |
|
SRPT
Sarepta Therapeutics, Inc.
|
$22.32 | $20.61 | $2.3B | 20.50x | $0.00 | 0% | 0.95x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IDYA
IDEAYA Biosciences, Inc.
|
2.43% | 1.755 | 1.14% | 12.20x |
|
GTBP
GT Biopharma, Inc.
|
-- | -0.510 | 4.06% | 1.98x |
|
PFE
Pfizer Inc.
|
39.94% | 0.301 | 42.51% | 0.81x |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
8.04% | 0.078 | 4.57% | 3.19x |
|
RZLT
Rezolute, Inc.
|
0.98% | 3.613 | 0.17% | 14.91x |
|
SRPT
Sarepta Therapeutics, Inc.
|
48.64% | -0.307 | 61.92% | 1.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IDYA
IDEAYA Biosciences, Inc.
|
$206.8M | $108.5M | -14.79% | -15.12% | 52.18% | $142.2M |
|
GTBP
GT Biopharma, Inc.
|
-- | -$3.4M | -626.24% | -626.24% | -- | -$3.7M |
|
PFE
Pfizer Inc.
|
$11.2B | $5.5B | 6.35% | 10.84% | 33.21% | $4B |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$3.1B | $1.1B | 14.07% | 15.37% | 29.56% | $1.4B |
|
RZLT
Rezolute, Inc.
|
-$8K | -$19.8M | -62.88% | -63.8% | -- | -$17.4M |
|
SRPT
Sarepta Therapeutics, Inc.
|
$230.1M | -$62.9M | -10.24% | -20.67% | -15.75% | -$55.6M |
IDEAYA Biosciences, Inc. vs. Competitors
-
Which has Higher Returns IDYA or GTBP?
GT Biopharma, Inc. has a net margin of 57.38% compared to IDEAYA Biosciences, Inc.'s net margin of --. IDEAYA Biosciences, Inc.'s return on equity of -15.12% beat GT Biopharma, Inc.'s return on equity of -626.24%.
Company Gross Margin Earnings Per Share Invested Capital IDYAIDEAYA Biosciences, Inc.99.5% $1.33 $1.1B GTBPGT Biopharma, Inc.-- -$0.83 $3M -
What do Analysts Say About IDYA or GTBP?
IDEAYA Biosciences, Inc. has a consensus price target of $49.65, signalling upside risk potential of 39.15%. On the other hand GT Biopharma, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 846.75%. Given that GT Biopharma, Inc. has higher upside potential than IDEAYA Biosciences, Inc., analysts believe GT Biopharma, Inc. is more attractive than IDEAYA Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IDYAIDEAYA Biosciences, Inc.13 2 0 GTBPGT Biopharma, Inc.1 0 0 -
Is IDYA or GTBP More Risky?
IDEAYA Biosciences, Inc. has a beta of 0.040, which suggesting that the stock is 96.023% less volatile than S&P 500. In comparison GT Biopharma, Inc. has a beta of 1.524, suggesting its more volatile than the S&P 500 by 52.367%.
-
Which is a Better Dividend Stock IDYA or GTBP?
IDEAYA Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GT Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDEAYA Biosciences, Inc. pays -- of its earnings as a dividend. GT Biopharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDYA or GTBP?
IDEAYA Biosciences, Inc. quarterly revenues are $207.8M, which are larger than GT Biopharma, Inc. quarterly revenues of --. IDEAYA Biosciences, Inc.'s net income of $119.2M is higher than GT Biopharma, Inc.'s net income of -$3.1M. Notably, IDEAYA Biosciences, Inc.'s price-to-earnings ratio is -- while GT Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEAYA Biosciences, Inc. is 14.69x versus 59.35x for GT Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDYAIDEAYA Biosciences, Inc.14.69x -- $207.8M $119.2M GTBPGT Biopharma, Inc.59.35x -- -- -$3.1M
-
Which has Higher Returns IDYA or PFE?
Pfizer Inc. has a net margin of 57.38% compared to IDEAYA Biosciences, Inc.'s net margin of 21.32%. IDEAYA Biosciences, Inc.'s return on equity of -15.12% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital IDYAIDEAYA Biosciences, Inc.99.5% $1.33 $1.1B PFEPfizer Inc.67.15% $0.62 $154.8B -
What do Analysts Say About IDYA or PFE?
IDEAYA Biosciences, Inc. has a consensus price target of $49.65, signalling upside risk potential of 39.15%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 14.36%. Given that IDEAYA Biosciences, Inc. has higher upside potential than Pfizer Inc., analysts believe IDEAYA Biosciences, Inc. is more attractive than Pfizer Inc..
Company Buy Ratings Hold Ratings Sell Ratings IDYAIDEAYA Biosciences, Inc.13 2 0 PFEPfizer Inc.7 15 1 -
Is IDYA or PFE More Risky?
IDEAYA Biosciences, Inc. has a beta of 0.040, which suggesting that the stock is 96.023% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.
-
Which is a Better Dividend Stock IDYA or PFE?
IDEAYA Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.87% to investors and pays a quarterly dividend of $0.43 per share. IDEAYA Biosciences, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.
-
Which has Better Financial Ratios IDYA or PFE?
IDEAYA Biosciences, Inc. quarterly revenues are $207.8M, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. IDEAYA Biosciences, Inc.'s net income of $119.2M is lower than Pfizer Inc.'s net income of $3.6B. Notably, IDEAYA Biosciences, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 14.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEAYA Biosciences, Inc. is 14.69x versus 2.28x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDYAIDEAYA Biosciences, Inc.14.69x -- $207.8M $119.2M PFEPfizer Inc.2.28x 14.59x $16.7B $3.6B
-
Which has Higher Returns IDYA or REGN?
Regeneron Pharmaceuticals, Inc. has a net margin of 57.38% compared to IDEAYA Biosciences, Inc.'s net margin of 38.89%. IDEAYA Biosciences, Inc.'s return on equity of -15.12% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.
Company Gross Margin Earnings Per Share Invested Capital IDYAIDEAYA Biosciences, Inc.99.5% $1.33 $1.1B REGNRegeneron Pharmaceuticals, Inc.82.47% $13.62 $33.7B -
What do Analysts Say About IDYA or REGN?
IDEAYA Biosciences, Inc. has a consensus price target of $49.65, signalling upside risk potential of 39.15%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $788.28 which suggests that it could grow by 0.58%. Given that IDEAYA Biosciences, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe IDEAYA Biosciences, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IDYAIDEAYA Biosciences, Inc.13 2 0 REGNRegeneron Pharmaceuticals, Inc.14 8 0 -
Is IDYA or REGN More Risky?
IDEAYA Biosciences, Inc. has a beta of 0.040, which suggesting that the stock is 96.023% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.
-
Which is a Better Dividend Stock IDYA or REGN?
IDEAYA Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.45% to investors and pays a quarterly dividend of $0.88 per share. IDEAYA Biosciences, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDYA or REGN?
IDEAYA Biosciences, Inc. quarterly revenues are $207.8M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. IDEAYA Biosciences, Inc.'s net income of $119.2M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, IDEAYA Biosciences, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEAYA Biosciences, Inc. is 14.69x versus 6.06x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDYAIDEAYA Biosciences, Inc.14.69x -- $207.8M $119.2M REGNRegeneron Pharmaceuticals, Inc.6.06x 18.76x $3.8B $1.5B
-
Which has Higher Returns IDYA or RZLT?
Rezolute, Inc. has a net margin of 57.38% compared to IDEAYA Biosciences, Inc.'s net margin of --. IDEAYA Biosciences, Inc.'s return on equity of -15.12% beat Rezolute, Inc.'s return on equity of -63.8%.
Company Gross Margin Earnings Per Share Invested Capital IDYAIDEAYA Biosciences, Inc.99.5% $1.33 $1.1B RZLTRezolute, Inc.-- -$0.18 $148.6M -
What do Analysts Say About IDYA or RZLT?
IDEAYA Biosciences, Inc. has a consensus price target of $49.65, signalling upside risk potential of 39.15%. On the other hand Rezolute, Inc. has an analysts' consensus of $4.13 which suggests that it could grow by 50.55%. Given that Rezolute, Inc. has higher upside potential than IDEAYA Biosciences, Inc., analysts believe Rezolute, Inc. is more attractive than IDEAYA Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IDYAIDEAYA Biosciences, Inc.13 2 0 RZLTRezolute, Inc.5 4 0 -
Is IDYA or RZLT More Risky?
IDEAYA Biosciences, Inc. has a beta of 0.040, which suggesting that the stock is 96.023% less volatile than S&P 500. In comparison Rezolute, Inc. has a beta of 0.211, suggesting its less volatile than the S&P 500 by 78.913%.
-
Which is a Better Dividend Stock IDYA or RZLT?
IDEAYA Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rezolute, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDEAYA Biosciences, Inc. pays -- of its earnings as a dividend. Rezolute, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDYA or RZLT?
IDEAYA Biosciences, Inc. quarterly revenues are $207.8M, which are larger than Rezolute, Inc. quarterly revenues of --. IDEAYA Biosciences, Inc.'s net income of $119.2M is higher than Rezolute, Inc.'s net income of -$18.2M. Notably, IDEAYA Biosciences, Inc.'s price-to-earnings ratio is -- while Rezolute, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEAYA Biosciences, Inc. is 14.69x versus -- for Rezolute, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDYAIDEAYA Biosciences, Inc.14.69x -- $207.8M $119.2M RZLTRezolute, Inc.-- -- -- -$18.2M
-
Which has Higher Returns IDYA or SRPT?
Sarepta Therapeutics, Inc. has a net margin of 57.38% compared to IDEAYA Biosciences, Inc.'s net margin of -45.06%. IDEAYA Biosciences, Inc.'s return on equity of -15.12% beat Sarepta Therapeutics, Inc.'s return on equity of -20.67%.
Company Gross Margin Earnings Per Share Invested Capital IDYAIDEAYA Biosciences, Inc.99.5% $1.33 $1.1B SRPTSarepta Therapeutics, Inc.57.63% -$1.80 $2.6B -
What do Analysts Say About IDYA or SRPT?
IDEAYA Biosciences, Inc. has a consensus price target of $49.65, signalling upside risk potential of 39.15%. On the other hand Sarepta Therapeutics, Inc. has an analysts' consensus of $20.61 which suggests that it could fall by -7.67%. Given that IDEAYA Biosciences, Inc. has higher upside potential than Sarepta Therapeutics, Inc., analysts believe IDEAYA Biosciences, Inc. is more attractive than Sarepta Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IDYAIDEAYA Biosciences, Inc.13 2 0 SRPTSarepta Therapeutics, Inc.7 14 3 -
Is IDYA or SRPT More Risky?
IDEAYA Biosciences, Inc. has a beta of 0.040, which suggesting that the stock is 96.023% less volatile than S&P 500. In comparison Sarepta Therapeutics, Inc. has a beta of 0.537, suggesting its less volatile than the S&P 500 by 46.348%.
-
Which is a Better Dividend Stock IDYA or SRPT?
IDEAYA Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IDEAYA Biosciences, Inc. pays -- of its earnings as a dividend. Sarepta Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IDYA or SRPT?
IDEAYA Biosciences, Inc. quarterly revenues are $207.8M, which are smaller than Sarepta Therapeutics, Inc. quarterly revenues of $399.4M. IDEAYA Biosciences, Inc.'s net income of $119.2M is higher than Sarepta Therapeutics, Inc.'s net income of -$179.9M. Notably, IDEAYA Biosciences, Inc.'s price-to-earnings ratio is -- while Sarepta Therapeutics, Inc.'s PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IDEAYA Biosciences, Inc. is 14.69x versus 0.95x for Sarepta Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IDYAIDEAYA Biosciences, Inc.14.69x -- $207.8M $119.2M SRPTSarepta Therapeutics, Inc.0.95x 20.50x $399.4M -$179.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
